Skip to content

Human Breast Tissue Bioavailability of Topically Applied Limonene

Human Breast Tissue Bioavailability of Topically Applied Limonene

Status
Completed
Phases
Phase 1
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT01459172
Enrollment
103
Registered
2011-10-25
Start date
2007-10-31
Completion date
2010-03-31
Last updated
2016-04-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Breast Cancer

Keywords

breast cancer prevention

Brief summary

The overall objective of this project is to determine the safety and breast tissue bioavailability of limonene following massage application of limonene containing massage oil to the breast.

Interventions

OTHERlimonene containing massage oil

daily massage application to the breast for 4 weeks

Sponsors

United States Department of Defense
CollaboratorFED
University of Arizona
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
PREVENTION
Masking
NONE

Eligibility

Sex/Gender
FEMALE
Age
18 Years to 65 Years
Healthy volunteers
Yes

Inclusion criteria

* Women who are 18-65 years of age * ECOG performance status 0-1 * Normal organ and marrow function * Women of child-bearing potential must agree to use adequate contraception * Willing to avoid consumption and use of citrus or citrus containing products throughout the study * Have both breasts intact

Exclusion criteria

* Have had cancer(s) within the past 5 years * Participated in another clinical interventional trial within the past 3 months * Uncontrolled intercurrent illness * Pregnant or breast feeding * Unable to produce nipple aspirate fluid * Have known allergic or sensitive reactions to skin care products, citrus or coconut oil * Have ongoing skin disorders such as eczema and psoriasis

Design outcomes

Primary

MeasureTime frameDescription
breast tissue bioavailability4 weekslimonene levels in nipple aspirate fluid after 4 weeks of intervention

Secondary

MeasureTime frameDescription
safety6 weeksnumber of participants with adverse events

Countries

United States

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026